Details of the Drug Combinations

General Information of This Drug (ID: DMYHBKN)

Drug Name
Exenatide   DMYHBKN
Synonyms Exenatide Synthetic; AC 2993 LAR; Ex4 peptide; Byetta (TN); Exendin 4 (Heloderma suspectum); Extendin-4; L-Serinamide
Indication
Disease Entry ICD 11 Status REF
Inflammation 1A00-CA43.1 Approved [1]
Non-insulin dependent diabetes 5A11 Approved [1]
Type-1/2 diabetes 5A10-5A11 Approved [1]
Type-2 diabetes 5A11 Approved [2]
Cardiovascular disease BA00-BE2Z Phase 3 [3]
Therapeutic Class
Hypoglycemic Agents
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

11 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Acarbose + Exenatide DC98LUG Acarbose Hyperinsulinemic Hypoglycemia [4]
Dapagliflozin + Exenatide DC3SWDM Dapagliflozin Evaluate Ketogenic Stress [5]
Liraglutide + Exenatide DC0AML7 Liraglutide Diabetes [6]
Nicotine + Exenatide DC453R7 Nicotine Smoking Cessation [7]
Rosiglitazone + Exenatide DCVH3SK Rosiglitazone Diabetes Mellitus, Type 2 [8]
Sitagliptin + Exenatide DCKPDVR Sitagliptin Type 2 Diabetes Mellitus [9]
Dapagliflozin + Exenatide DCEBEX7 Dapagliflozin Obesity [10]
Nicotine + Exenatide DCBLAW4 Nicotine Smoking Cessation [11]
Insulin-glargine + Exenatide DCJLJC7 Insulin-glargine Type 2 Diabetes [12]
Metformin + Exenatide DC4KY92 Metformin Polycystic Ovary Syndrome [13]
Saxagliptin + Exenatide DC5KBFV Saxagliptin Prediabetes [14]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 DrugCom(s)

References

1 Exenatide FDA Label
2 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 ClinicalTrials.gov (NCT02685852) Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia
5 ClinicalTrials.gov (NCT02962492) An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes
6 ClinicalTrials.gov (NCT01676116) The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy
7 ClinicalTrials.gov (NCT02975297) Exenatide Once Weekly for Smoking Cessation
8 ClinicalTrials.gov (NCT00135330) An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus
9 ClinicalTrials.gov (NCT00477581) A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes Mellitus
10 ClinicalTrials.gov (NCT02313220) Exploratory Study to Investigate the Effect of Dapagliflozin and Exenatide Combined on Body Weight
11 ClinicalTrials.gov (NCT05610800) Exenatide for Smoking Cessation and Prevention of Weight Gain
12 ClinicalTrials.gov (NCT02455076) Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta) Therapy for the Inpatient Management of Patients With Type 2 Diabetes
13 ClinicalTrials.gov (NCT04029272) Metformin vs Metformin Combined With GLP-1RA (Glucagon-like Peptide 1 Receptor Agonist) on Overweight/Obese PCOS Patients
14 ClinicalTrials.gov (NCT02104739) Effects of Antidiabetic Medications on the Postprandial State in Prediabetes